Medpace Holdings, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Susan E Burwig, Exec. VP, Operations of Medpace Holdings, Inc., reported multiple transactions in common stock on October 12, 2026.
NASDAQ
Susan E Burwig, Exec. VP, Operations of Medpace Holdings, Inc., reported multiple transactions in common stock on October 7, 2026.
NASDAQ
Cornelius P. Mccarthy Iii, a Director of Medpace Holdings, Inc., reported multiple transactions in common stock on September 30, 2026.
NASDAQ
Robert O. Kraft, a Director of Medpace Holdings, Inc., reported multiple transactions in common stock on September 30, 2026.
NASDAQ
Brian T Carley, a Director of Medpace Holdings, Inc., reported multiple transactions in common stock on September 30, 2026.
NASDAQ
August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 48,667 shares of common stock on September 29, 2026.
NASDAQ
August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 2,564 shares of common stock on September 25, 2026.
NASDAQ
August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 70,901 shares of common stock on September 21, 2026.
NASDAQ
August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 10,880 shares of common stock on September 17, 2026 for $620.40 per share.
NASDAQ
August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 24,741 shares of common stock on September 15, 2026.
NASDAQ
Susan E Burwig, Exec. VP, Operations of Medpace Holdings, Inc., reported multiple transactions in common stock on September 15, 2026.
NASDAQ
August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 650 shares of common stock on August 27, 2026 for $620.27 per share.
NASDAQ
Robert O. Kraft, a Director of Medpace Holdings, Inc., sold 3,858 shares of common stock on August 26, 2026 for $617.81 per share.
NASDAQ
August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 4,673 shares of common stock on August 25, 2026.
NASDAQ
August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 15,978 shares of common stock on August 21, 2026.
NASDAQ
Kevin M. Brady, CFO & Treasurer of Medpace Holdings, Inc., sold 3,400 shares of common stock on August 20, 2026 for $625.24 per share.
NASDAQ
August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 42,783 shares of common stock on August 19, 2026.
NASDAQ
Brian T Carley, a Director of Medpace Holdings, Inc., sold 5,000 shares of common stock on August 19, 2026 for $608.63 per share.
NASDAQ
Fred B Davenport Jr, a Director of Medpace Holdings, Inc., sold 7,283 shares of common stock on August 19, 2026 for $606.15 per share.
NASDAQ
August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 23,144 shares of common stock on August 10, 2026.
NASDAQ
Cornelius P. Mccarthy Iii, a Director of Medpace Holdings, Inc., sold 795 shares of common stock on August 7, 2026 for $585.07 per share.
NASDAQ
August J. Troendle, President & CEO, a Director and 10% owner of Medpace Holdings, Inc., sold 7,238 shares of common stock on July 27, 2026.
NASDAQ
Susan E Burwig, Exec. VP, Operations of Medpace Holdings, Inc., sold 7,500 shares of common stock on July 28, 2026 for $600.00 per share.
NASDAQ
Robert O. Kraft, a Director at Medpace Holdings, Inc., has acquired 33 restricted stock units, converting them into common stock.
NASDAQ
Stephen P. Ewald, General Counsel & Corp. Secy. of Medpace Holdings, Inc., reported transactions involving the acquisition and disposition of common stock.
NASDAQ
Medpace Holdings, Inc. director Dani S. Zander was granted 1,110 stock options as part of standard board compensation.
NASDAQ
Medpace Holdings, Inc. director Cornelius P. McCarthy III was granted 1,110 stock options as part of standard equity compensation.
NASDAQ
Director Robert O. Kraft was granted 1,110 stock options in Medpace Holdings, Inc. as part of standard equity compensation.
NASDAQ
Director Femida H. Gwadry-Sridhar was granted 1,110 stock options in Medpace Holdings, Inc. as part of standard equity compensation.
NASDAQ
Fred B. Davenport Jr., a Director and 10% Owner of Medpace Holdings, Inc., acquired 1,110 stock options with an exercise price of $415.27, vesting based on service.